In this study, the antibacterial and cytotoxic activities of some amino acid methyl esters (L-methionine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, and L-tyrosine) were investigated. The effect of amino acid methyl ester compounds on antibacterial performance was determinated against Gram-negative and Gram-positive bacteria. The effect of amino acid esters on cell viability was investigated against cancerous and non-cancerous cell lines using the MTS assay. The results showed the substances had low antimicrobial effect on both Gram-negative and Gram-positive bacteria. In addition, it was found that the studied substances did not have a toxic effect on cell growth in non-cancerous cells. For this reason, it is thought that the results obtained will contribute to research on new synthesizable compounds based on amino acid esters and studies on drug development.
15 August 2023 in Turkish Journal of Gastroenterology
Background/Aims: Sine oculis homeoprotein 1 exerts an essential role in embryonic development, and it was also identified to be reactivated in various types of mammalian cancer. The sine oculis homeoprotein 1 transcription factor was demonstrated to induce epithelial–mesenchymal transition, regulate crucial genes associated with cancer progression, and increase the oncogenic potential of cells. Therefore, the present study aimed to identify the role of sine oculis homeoprotein 1 in cancer. Materials and Methods: Sine oculis homeoprotein 1 gene expression was tested with real-time quantitative polymerase chain reaction (PCR) in different cancer types. Sine oculis homeoprotein 1 expression was suppressed by short hairpin RNA transduction in the SNU398 hepatocellular carcinoma cell line. The effects of sine oculis homeoprotein 1 on cell proliferation, drug resistance, and sphere formation were assessed in shSIX1 cells. Immunohistochemical and in silico analyses were performed to determine the prognostic role of sine oculis homeoprotein 1 expression. Results: The upregulated expression levels of sine oculis homeoprotein 1 were revealed to be correlated with the stage of the disease in breast, colon, and liver cancer, with liver cancer exhibiting the highest expression profile. Sine oculis homeoprotein 1 downregulation significantly affected cell proliferation and suppressed sorafenib resistance and sphere-forming ability. Furthermore, sine oculis homeoprotein 1 knockdown cells were identified to have decreased CD90 levels, essential for cancer stem cell properties. Finally, sine oculis homeoprotein 1 expression was a CD90-independent biomarker for the clinical prognosis of liver cancer. Conclusion: The results of this study showed that the knockdown of sine oculis homeoprotein 1 expression might help to prevent hepatocarcinogenesis by increasing drug sensitivity and controlling tumor sphere formation. Overall, these results indicated that sine oculis homeoprotein 1 expression might be useful as a diagnostic marker for patients with hepatocellular carcinoma. Cite this article as: Balçık-Erçin P, Aysan A, Salık N, Erciyas E. SIX1 downregulation suppresses self-renewal capacity and THY1 expression in hepatocellular carcinoma and SIX1 dominate the survival in liver cancer. Turk J Gastroenterol. 2023;34(8):881-889.
Antibiotic resistance is a growing problem in the treatment of life-threatening diseases. Recently, a variety of covalent drugs have emerged. Cysteine is one of the least abundant amino acids in the proteins of many organisms, and the thiol group in its structure makes it unique and has become a common covalent amino acid residue in covalent drug development. Therefore, it is important to conduct research on cysteine derivatives. In this study, the in vitro antibacterial activity of L-cysteine esters were tested against Gram-positive Staphylococcus aureus and Gram-negative Escherichia coli using the modified microdilution broth method. In vitro cytotoxic activities of the esters were carried out against the healthy HEK293T cell line and well-differentiated liver cancer cell lines PLC/PRF/5 and HEP3B at different concentrations by using an MTS assay. In addition, molecular docking studies, ADMET properties, and drug-likeness were also reported. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable cysteine-based drugs. In conclusion, a thorough examination of the frontier orbital (HOMO and LUMO) and MEP studies was conducted using quantum chemistry techniques to determine the molecule’s reactivity, electrophilic and nucleophilic sites.
1 October 2025 in Hacettepe Journal of Biology and Chemistry
The increasing the importance of synthesizing compounds with high biocompatibility, low cytotoxicity, and advanced antibacterial properties is evident in current research. L-3,4-Dihydroxyphenylalanine (L-DOPA) is a crucial drug widely used in the treatment of Parkinson's disease. In this study, we investigated the antimicrobial and cytotoxic effects of L-DOPA and its water-soluble derivative, L-DOPA methyl ester. The antimicrobial effects of L-DOPA and L-DOPA Methyl Ester were tested on both Gram-negative and Gram-positive bacteria. Additionally, the impact of L-DOPA and its ester on cell viability was assessed using the MTT assay on cancerous and non-cancerous cell lines. The study revealed that both substances were effective against Gram-positive bacteria but not Gram-negative bacteria. Specifically, the growth of Gram-positive bacteria was inhibited by both compounds, with L-DOPA showing greater efficacy. We also observed that L-DOPA and its ester exhibit anti-cancer activity. Furthermore, the molecular docking mechanism between the three targets (2DS2, 4URO and 1M17) and the compounds was investigated using Autodock Vina. The findings show that the L-DOPA molecule is more appropriately attached to the target receptors than the L-DOPA methyl ester molecule. As a result, its inhibition is greater. The results obtained are new and it is thought that these results of the study will contribute to the development of new synthesizable drug studies.
Background/aim: Targeted therapies with monoclonal antibodies provide cancer patients with better prognosis and diseasefree survival. The blockade of immune checkpoints, including programmed cell death protein-1 (PD-1) and its ligand PD-L1, with monoclonal antibodies may boost immune responses against tumors and is regarded as an effective strategy in cancer immunotherapy. We describe the generation of anti-PD-L1 monoclonal antibodies with high affinity and specificity, and we assess their potential for therapeutic use in cancer. Materials and methods: Hybridomas were selected for PD-L1 specificity and cross-reactivity with other immune checkpoint proteins and PD-L1 orthologs using indirect ELISA. Immunofluorescence and Western blotting assays were conducted for further characterization of the antibodies. The affinities of the antibodies for PD-L1 were determined using surface plasmon resonance. Receptor blocking activities were examined through competitive ELISA and cell-based luciferase reporter assays. Sequences of variable regions of the selected antibodies were determined by Sanger sequencing and subjected to BLAST analysis. Results: A total of 25 PD-L1-specific monoclonal antibodies were generated. While most clones reacted with PD-L1 from cynomolgus monkeys, none of the antibodies displayed cross-reactivity with other checkpoint proteins. Immunofluorescence assays showed that the selected clones stained PD-L1-expressing cell membranes specifically, but not those of PD-L1-negative cells. Western blotting revealed that most of the clones recognized both glycosylated and nonglycosylated PD-L1, and a few reacted with the glycosylated form only. Only two clones with subnanomolar affinity for human PD-L1 were effective at blocking PD-1/PD-L1 and CD80/PD-L1 interactions. Sequence analysis of their variable regions revealed their unique specificity. Conclusion: Of the 25 monoclonal antibodies produced in this study, only one was identified as a potential therapeutic drug candidate thanks to its high capacity for checkpoint blockade and affinity, as well as its unique sequence specificity. These properties are comparable to those of anti-PD-L1 antibodies currently used in clinical practice.